Venmax Drugs Turns Profitable with ₹24.82 Lakh Net Profit in FY26
Venmax Drugs & Pharmaceuticals Limited returned to profitability in FY26, posting a net profit of ₹24.82 lakh against a prior year loss, with revenue from operations surging to ₹802.49 lakh. The Board approved results on May 14, 2026, and newspaper advertisements were published on May 15, 2026 per SEBI Regulation 47. Total assets grew to ₹1620.02 lakh, supported by equity expansion through conversion of 63,44,000 share warrants.
*this image is generated using AI for illustrative purposes only.
Venmax Drugs & Pharmaceuticals Limited has reported its audited standalone financial results for the quarter and year ended March 31, 2026, recording a return to profitability. The company posted a net profit of ₹24.82 lakh for the year, a reversal from the net loss of ₹1.05 lakh reported in the previous fiscal year. The Board of Directors approved the results at a meeting held on May 14, 2026. In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published newspaper advertisements of the financial results in "Financial Express" and "Nava Telangana" on May 15, 2026. The financial results and audit report have also been made available on the company's website at www.venmaxdrugs.com .
The financial performance was driven by a substantial increase in operational scale. Revenue from operations for the year stood at ₹802.49 lakh, a sharp rise compared to ₹80.73 lakh in the corresponding period of the previous year. Total revenue, which includes other income, amounted to ₹818.53 lakh for the year ended March 31, 2026.
Financial Performance Overview
The company's expenses for the year totaled ₹790.83 lakh. Profit before tax for the year was recorded at ₹27.70 lakh, compared to a loss before tax of ₹1.41 lakh in the prior year. The Audit Committee reviewed and recommended the figures before the Board's approval. The following table summarises the key financial metrics for the reporting period:
Key Financial Metrics
| Particulars: | Year Ended 31/03/2026 (Audited) | Year Ended 31/03/2025 (Audited) |
|---|---|---|
| Revenue from Operations: | ₹802.49 lakh | ₹80.73 lakh |
| Total Revenue: | ₹818.53 lakh | ₹186.05 lakh |
| Total Expenses: | ₹790.83 lakh | ₹187.46 lakh |
| Profit / (Loss) for the Year: | ₹24.82 lakh | (₹1.05) lakh |
| Earnings Per Share: | ₹0.21 | (₹0.02) |
Balance Sheet and Cash Flow
As of March 31, 2026, the company's total assets stood at ₹1620.02 lakh, a significant increase from ₹516.96 lakh in the previous year. This growth was largely attributed to a rise in current assets, which reached ₹1616.36 lakh. Equity share capital increased to ₹1158.29 lakh, bolstered by the conversion of 63,44,000 share warrants into equity shares during the year at a face value of ₹10 and a premium of ₹10 each.
Cash and cash equivalents decreased to ₹122.36 lakh as of March 31, 2026, from ₹248.24 lakh in the prior year. The net cash flow from operating activities was negative at ₹(1099.61) lakh, primarily due to changes in working capital. However, financing activities provided a net inflow of ₹973.73 lakh, largely driven by share application money pending allotment. The results were submitted to BSE Limited in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and were signed by Managing Director Venkata Rao Sadhanala (DIN: 02906370) from Hyderabad.
Historical Stock Returns for Venmax Drugs & Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.46% | +3.40% | -6.54% | -19.73% | -9.06% | +264.74% |
Can Venmax Drugs sustain its nearly 10x revenue growth trajectory in FY2027, or was the ₹802.49 lakh figure driven by one-time contracts that may not recur?
Given the deeply negative operating cash flow of ₹(1099.61) lakh despite reported profitability, how will the company manage its working capital requirements and liquidity position going forward?
With equity share capital significantly expanded through warrant conversions and share application money pending allotment, what are the company's planned deployment strategies for the newly raised capital?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
